Treatment | TD50 | TD50 (DZP + Vehicle) | ED50 | ED50 (DZP + Vehicle) | PI | ||
---|---|---|---|---|---|---|---|
TD50 (combination) | ED50(combination) | ||||||
DZP + vehicle | 3.13 | 1 | 0.26 | 1 | 12.0 | ||
(1.88–5.23) | (0.15–0.45) | ||||||
DZP + 3α,5α-P (1.7) | 2.05 | 1.5 | 0.0353-a | 7.4 | 58.6 | ||
(1.31–3.23) | (0.0013–0.091) | ||||||
DZP + 3α,5β-P (3) | 1.50 | 2.1 | 0.00673-a | 38.8 | 224 | ||
(0.80–2.80) | (0.0012–0.038) | ||||||
DZP + Ganaxolone (3) | 1.73 | 1.8 | 0.00533-a | 49.1 | 326 | ||
(0.91–3.29) | (0.0012–0.023) | ||||||
DZP + Co 2-1068 (3) | 2.51 | 1.2 | 0.00703-a | 37.1 | 359 | ||
(1.06–5.95) | (0.0010–0.048) | ||||||
DZP + PB (3) | 2.88 | 1.1 | 0.00973-a | 26.8 | 297 | ||
(2.16–3.85) | (0.0033–0.029) |
The data represent the TD50 and ED50 values (in mg/kg with 95% confidence limits in parentheses) evaluated in DZP alone (DZP + vehicle) and DZP + drug-treated groups. Ratios of respective TD50 (DZP + vehicle)/TD50(combination) and ED50 (DZP + vehicle)/ED50(combination) as well as protective indices (PI = TD50/ED50) were calculated for combined treatments. The adjuvants were administered at their maximal ineffective doses against PTZ, as listed in parentheses (in mg/kg) next to respective names. TD50 values for combined treatments did not differ from that for (DZP + vehicle)-treated group.
↵3-a P < .05; compared to ED50 of (DZP + vehicle)-treated group (Litchfield and Wilcoxon, 1949).